Comparative Pharmacology
Head-to-head clinical analysis: FLOVENT DISKUS 250 versus METICORTEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOVENT DISKUS 250 versus METICORTEN.
FLOVENT DISKUS 250 vs METICORTEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone propionate is a corticosteroid with potent anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines, reduction of eosinophil recruitment, and suppression of airway hyperresponsiveness.
Prednisone is a prodrug that is converted to prednisolone, which binds to the glucocorticoid receptor, modulating gene expression and suppressing inflammation, immune response, and adrenal function.
250 mcg inhaled orally via DISKUS twice daily (500 mcg total daily dose).
5-60 mg orally once daily, depending on condition; for acute exacerbations, up to 250 mg IV every 4-6 hours.
None Documented
None Documented
Approximately 10-12 hours (terminal elimination half-life in asthmatics).
Following oral or IV administration, the terminal elimination half-life of total prednisolone (active form) is 2.1–3.5 hours in adults with normal hepatic function. In hepatic impairment, half-life may be prolonged (up to 6–8 hours), necessitating dose adjustment.
Renal (approximately 5% as unchanged drug); fecal (majority as metabolites and unabsorbed drug).
Primarily renal: approximately 80% as inactive metabolites (conjugated and oxidized forms) and <5% as unchanged prednisolone. Biliary/fecal excretion accounts for about 10-15% of the dose.
Category C
Category C
Corticosteroid
Corticosteroid